Study | Preinjection WOMAC total scores | Preinjection VAS scores | ||||
---|---|---|---|---|---|---|
LP-PRP | HA | P value | LP-PRP | HA | P value | |
Cerza, 2012 (Italy) [19] | 79.6 ± 9.5 | 75.4 ± 10.7 | 0.025 | N/A | N/A | N/A |
Sánchez, 2012 (Spain) [18] | 121.8 ± 44.4 (†Normalized WOMAC scale) | 115.6 ± 45.1 (†Normalized WOMAC scale) | 0.378 | N/A | N/A | N/A |
Say, 2012 (Turkey) [16] | N/A | N/A | N/A | 7.3 ± 1.6 | 7 ± 1.3 | 0.234 |
Vaquerizo, 2013 (Spain) [21] | 45.9 ± 12.7 | 50.8 ± 18.4 | 0.137 | N/A | N/A | N/A |
Montañez-Heredia, 2016 (Spain) [17] | N/A | N/A | N/A | N/A | N/A | N/A |
Cole, 2017 (USA) [26] | 7 ± 0.53 (WOMAC pain score) | 7.52 ± 0.58 (WOMAC pain score) | 0.0001 | 5.72 ± 1.43 | 6.29 ± 1.57 | 0.0619 |
Raeissadat, 2017 (Iran) [22] | 42.9 ± 13.5 | 38.8 ± 12.6 | 0.197 | 7.8 ± 1.78 | 7.4 ± 1.48 | 0.316 |
Louis, 2018 (France) [23] | 35.5 ± 15.5 | 32.5 ± 23.1 | 0.599 | 4.8 ± 2.3 | 5.0 ± 2.4 | 0.712 |
Buendía‐López, 2019 (Spain) [25] | 42.57 ± 7.3 | 42.62 ± 7.3 | 0.978 | 6.15 ± 1.1 | 6.06 ± 0.9 | 0.72 |
Huang, 2019 (China) [24] | 48.19 ± 4.96 | 47.23 ± 5.37 | > 0.05 | 4.57 ± 0.61 | 4.54 ± 0.6 | 0.825 |
Lin, 2019 (Taiwan) [20] | 52.8 ± 18.1 | 52.7 ± 18.1 | 0.601 | N/A | N/A | N/A |
Xu, 2021 (China) [15] | N/A | N/A | N/A | N/A | N/A | N/A |